Clinical Study of Yiqi Tongluo Prescription on Interventional Restenosis of Ischemic Cerebrovascular Disease

Dongfang Hospital of Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients with ischemic cerebrovascular disease were diagnosed by imaging examination;
•2. Patients aged 35-80 years old;
•3. Patients with endovascular interventional therapy;
•4. Patients with Qi deficiency, blood stasis and phlegm obstruction were diagnosed by TCM syndrome score scale;
•5. Patients with 0-2 scores of modified Rankin scale before onset of disease;
•6. Patients who voluntarily participated in the study and have signed informed consent.

•1. Patients who are expected to survive for less than 2 years;
•2. Patients with severe systemic diseases or unsuitable / intolerant dual antiplatelet therapy;
•3. Patients with severe neurological dysfunction (MRS score >= 3) before the stroke or TIA attack;
•4. Patients with severe myocardial infarction within 2 weeks;
•5. Patients with moyamoya disease, active arteritis and unexplained non atherosclerotic stenosis;
•6. Patients with international normalized ratio (INR) > 1.5;
•7. Pregnant women;
•8. Patients who are not suitable for endovascular therapy as judged by neurologists and Neurointerventional physicians.
•9. Patients with severe heart, liver and kidney damage;
•10. Patients with a history of mental illness and mental retardation.

发起方

Dongfang Hospital of Beijing University of Chinese Medicine